Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LPA Clear all
Completed Not applicable Interventional
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Dietary Intervention
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:15 PM EDT
Enrolling by invitation No phase listed Observational
View directory record Official record
Conditions
PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease
Interventions
C-11 PiB, AV1451 Tau, C-11 ER176
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced May 21, 2026, 7:15 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Lp(a) Screening
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
39,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Pelacarsen (TQJ230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
83
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Interventions
TQJ230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
89
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
Blood draw for Lp(a)
Diagnostic Test
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
180
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4954, Laroprovstat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions
SLN360, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3473329, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced May 21, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Sedentary Lifestyle, Risk Factor, Cardiovascular
Interventions
Treadmill desk
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AMG 890, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
7
States / cities
Tustin, California • Boca Raton, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Lipoprotein (a)
Interventions
Venipuncture
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, LIPA Deficiency, LAL-Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
19
States / cities
Phoenix, Arizona • Stanford, California • Miramar, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Dyslipidemias
Interventions
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
DII235, Saline
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia
Interventions
Supportive care
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Clark, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
Pelacarsen (TQJ230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
91
States / cities
Andalusia, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
133
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
8 Months and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced May 21, 2026, 7:15 PM EDT